Browsing Tag
Tirzepatide
36 posts
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Eli Lilly (LLY) reclaims a $1tn valuation as Wall Street bets on its next weight-loss drug
Eli Lilly reclaimed a $1 trillion valuation at a record high as Wall Street prices in retatrutide, its next-gen obesity drug, and the GLP-1 metabolic platform thesis.
MHRA weight-loss drug raid exposes black-market risk behind Britain’s slimming jab boom
Weight-loss jabs are booming, and criminals are following demand. The MHRA raid shows how illicit supply is becoming a patient safety threat.
Eli Lilly (NYSE: LLY) bets on oral GLP-1 Foundayo and retatrutide to reclaim its $1tn valuation
Eli Lilly (NYSE: LLY) launched Foundayo, the world's first oral GLP-1 for obesity, in April 2026 and reports Q1 earnings April 30. Full pipeline and risk analysis for retail investors.
Vanda Pharmaceuticals (VNDA) bets on GLP-1 adherence gap with new Nereus vomiting-prevention study
Vanda Pharmaceuticals has launched the Thetis study to test Nereus in GLP-1-related vomiting. Read what this means for obesity drug adherence and VNDA.
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
Why Eli Lilly’s Zepbound just tightened its grip on the obesity drug market in 2026
Find out how Eli Lilly and Company is strengthening Zepbound’s market dominance with a multi-dose KwikPen and reshaping obesity drug access in 2026.
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation?
OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development.
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.